BREAKING: Tech Futures Jump On Megacap Earnings Biogen stock edged higher Wednesday after the biotech company topped second-quarter expectations, but didn't shed much light on its Alzheimer's treatment efforts."After the recent Tecfidera (intellectual property) loss and the delay in aducanumab filing relative to expectations, investors like the beat and raise quarter," SVB Leerink analyst Marc Goodman said in a note.